pontaneous intracerebral hemorrhage (SICH) accounts for ≈10% to 30% of all strokes worldwide and is much more likely to result in death or severe neurological deficits than either ischemic stroke or subarachnoid hemorrhage. 1,2 Glasgow coma scale score, baseline hematoma volume, age, the presence of intraventricular hemorrhage, and hematoma expansion (HE) are all independent predictors of poor outcomes in patients with SICH. Of these, HE is the only potentially modifiable factor. [3][4][5][6] In the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial, 7 the use of hemostatic therapy to attenuate HE did not translate into improved outcomes, partly because patients who were destined to have HE were not specifically targeted which may have diluted any treatment effect.
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sign on CTP (such as number, timing of occurrence, and maximum density) and the risk of HE and clinical outcomes after SICH. Our aim was to improve the definition of the spot sign to increase both its detection rate and predictive value.
Materials and Methods
Patient Cohort
We retrospectively reviewed our prospectively collected database for consecutive patients with SICH who were admitted between June 2014 and August 2015. Patients aged ≥18 years who had a supratentorial SICH and underwent a noncontrast head CT (NCCT) followed by CTP acquisition within 6 h of onset and a follow-up NCCT at 24 hours were included. Exclusion criteria were (1) secondary ICH, including trauma, underlying aneurysm, or vascular malformation, hemorrhagic venous infarct, or hemorrhagic transformation of ischemic stroke; (2) infratentorial ICH; and (3) poor image quality (one patient was excluded because of severe head movement artifact and another because of incomplete consecutive acquisition). Patients who died before a follow-up CT was performed at 24 hour were excluded from the HE analysis, but included in the outcome analysis. Patients who underwent surgical evacuation of the hematoma were excluded from the outcome analysis; those who underwent evacuation before follow-up CT were also excluded from HE analysis.
Clinical Data
Baseline clinical variables were recorded in an ICH database, including patient demographics, medical history, medications, onset to imaging time, baseline National Institute of Health Stroke Scale (NIHSS), and laboratory results. Neurological outcomes including NIHSS at 24 hours, mortality in hospital, and modified Rankin Scale, including death at 3-month follow-up, were collected from the medical records.
Imaging Protocol
CTP was performed on a dual-source 64-slice CT scanner (SOMATOM Definition Flash; Siemens Healthcare Sector, Forchheim, Germany), including NCCT scan (120 kV, 320 mA, contiguous 5 mm axial slices) and whole-brain volume perfusion computed tomography (100 mm in the z-axis, 4 seconds delay after start of contrast medium injection, 74.5 seconds total imaging duration, 80 kV, 120 mA, slice thickness 1.5 mm, collimation 32×1.2 mm). Volume perfusion computed tomography consisted of 26 consecutive spiral acquisitions of the brain. All 26 scans were divided into 4 parts: (1) 2 scans with 3-second cycle time; (2) 15 scans with 1.5-seconds cycle time; (3) 4 scans with 3-seconds cycle time; and (4) 5 scans with 6-seconds cycle time. Axial slice coverage was 150 mm. A 60-mL bolus of contrast medium (Iopamidol; Braccosine, Shanghai, China) with a single injection was used at a flow rate of 6 mL/s, followed by a 20 mL saline chaser at 6 mL/s. The effective dose (calculated by multiplying dose-length products with published conversion factors) was 5.94 mSV for volume perfusion computed tomography acquisition and 1.82 mSV for NCCT acquisition. As described by Frolich et al, baseline 4D CTA images were reconstructed in axial, coronal, and sagittal with 20-mm-thick slabs. 15 The follow-up head NCCT was obtained within 24 hours of the CTP examination.
Assessment of CTP Spot Sign
Two experienced neurologists blinded to the patients' clinical data jointly reviewed and reconstructed all admission CTP images by using commercial software (MIStar; Apollo Medical Imaging Technology, Melbourne, VIC, Australia). Spot sign was visualized on spot windows (width, 200; level, 110) on CTP. 9 The CTP spot sign was defined according to the following criteria: (1) ≥1 focus (attenuation ≥120 HU) of any size and morphology within the ICH, (2) not visualized at the corresponding location on NCCT images, (3) discontinuous from normal or abnormal vasculature adjacent to the ICH, and (4) can be visualized in the follow-up continuous imaging of the same slice after presence. 10, [12] [13] [14] Discrepancies were resolved by consensus. Timing of occurrence (time from the start of CTP scanning to first detection of spot sign), total number of spots, maximum spot attenuation (maximum attenuation among all phases where spot sign was present), axial dimensions (largest spot size in the axial CTP source image) were recorded by locating the specific slices and frame. In CTPs with >1 spot sign, the characterization was performed on the earliest spot sign identified.
Assessment of Radiographic and Clinical Outcome
Hematoma volumes were calculated on the initial and follow-up NCCT by planimetric method. Briefly, regions of interest were manually drawn by tracing the perimeters of the hematoma in each slice throughout the hemorrhagic lesion. The traced regions of interest in the contiguous voxels were then summed automatically after adjusting for the slice thickness to yield a hematoma volume (MIStar). 16 Intraventricular hemorrhage volume was not included in the volume analysis, but recorded by using Modified Graeb score. 17 Absolute ICH growth (follow-up volume−baseline volume) and relative ICH growth [(follow-up volume−baseline volume)/baseline volume)] were calculated, respectively. HE was defined as an absolute ICH growth ≥6 mL or relative growth ≥33%. 10 Poor outcome included early neurological worsening (defined as worsening of ≥4 points in the NIHSS score at 24 hours compared with baseline) and mortality.
10
Statistical Analysis
Results were delineated as the mean±SD or interquartile rangefor quantitative variables and as proportions for categorical variables. Inter-rater and intrarater reliability for hematoma volumes and detection of spot sign were assessed by the intraclass correlation coefficients and the kappa statistic. Continuous data were assessed by using 2-tailed t test or Mann-Whitney U test. Categorical data were assessed by using the Fisher exact test. The Spearman correlation coefficient was used to determine the correlation between timing of spot sign occurrence and ICH volume growth (absolute and relative). Variables with a P<0.05 in univariate regression analyses were included in the multivariate logistic regression models. Baseline NIHSS score, glucose level, previous use of antiplatelet and baseline hematoma volume, which were thought to be potential factors associated with HE, were forced into the model. 18 Receiver operating characteristic curve analysis was taken to identify the predictive performance of characteristics of spot sign for HE. All statistical analyses were performed using SPSS, Version 19.0 (IBM, Armonk, New York). A P value <0.05 was considered statistically significant.
Results
A total of 83 patients met the eligibility criteria for this study. The mean age was 65.49±15.20 years; 21 patients (25.3%) were women; and median baseline NIHSS score was 12 (7) (8) (9) (10) (11) (12) (13) (14) (15) . Spot sign was detected in 46% (38/83) of patients. The location of ICH was lobar in 10/83 (12%) and deep in 73/83 (88%). Eleven patients (6 with positive spot sign) did not undergo follow-up NCCT within 24 hours; therefore, only the remaining 72 patients (83−11) were included in the analysis of HE. The excluded patients had higher systolic blood pressure (208±39 mm Hg versus 176±39 mm Hg; P=0.016), higher diastolic blood pressure (123±27 mm Hg versus 100±22 mm Hg; P=0.002), greater median baseline hematoma volume (52.30 mL versus 15.80 mL; P=0.029), and higher median NIHSS score (21 versus 11; P=0.004) compared with the remaining patients. Twelve patients (including one with follow-up CT, 7 patients with positive spot sign) underwent surgical hematoma evacuation, and the remaining 71 (83−12) patients were included for the analysis of outcome. Inter-rater and intrarater kappa value for detection of the spot sign were 0.89 and 1.00; and inter-rater and intrarater intraclass correlation coefficients for hematoma volumes were 0.99 and 0.98. All CTP acquisitions achieved full hematoma coverage.
As summarized in Tables 1 and 2 , patients with positive spot sign had higher median baseline ICH volume (22.9 mL versus 13.1 mL; P=0.037), greater median volume of hematoma growth (5.60 mL versus 0.06 mL; P=0.043), and higher median modified Rankin Scale score (4 versus 3; P=0.004) and mortality rate (32% versus 8%; P=0.012) at 3 months, compared with patients without spot sign. Hematoma expansion, using different definitions, was significantly more frequent in the spot sign-positive group than in the spot signnegative group (all P<0.05). 
Analysis of Risk Factors for HE and Mortality
We compared the baseline characteristics between patients with and without HE and found that the rate of spot sign was higher in HE patients than in those without HE (62.5% versus 12.5%; P<0.001). With multivariate analysis ( Among all of the characteristics of spot sign listed in Table 4 , the timing of occurrence had the greatest area under receiver operating characteristic curve (0.781; 95% CI, 0.603-0.958; P=0.014). Early-occurring spot sign (EOSS), that is, spot sign detected before 23.13 seconds, had sensitivity of 0.67 and specificity of 0.90. On multivariable analysis, EOSS was an independent predictor of HE (odds ratio=28.835; 95% CI, 6.960-119.458; P<0.001) and 3-month mortality (odds ratio=22.377; 95% CI, 1.773-282.334; P=0.016). The predictive performance of the spot sign and EOSS is shown in Table 5 and Figure. EOSS maintained a higher specificity for HE compared with spot sign (91% versus 74%).
Discussion
In this cohort of SICH patients, spot sign on CTP was associated with HE. Furthermore, we found that the timing of spot sign occurrence was the most important characteristic of spot sign for predicting HE. The predictive ability of HE was highest for spot sign that was detected before 23.13 seconds (EOSS). EOSS was also an independent predictor of 3-month mortality.
In our study, the median time from symptom onset to CTP was 180 (120-240) minutes. The overall prevalence rate of spot sign in our cohort was ≈46%; 66% of which were EOSS. This is higher than most previous reported rates (18% to 50%). [8] [9] [10] [11] [12] [13] [14] 19 In the predicting hematoma growth and outcome in interracial hemorrhage using contrast bolus CT (PREDICT) study, the largest prospective study using CTA to detect the spot sign, the median time from symptom onset to CTA was 159 (32-475) minutes, and 30% of patients were spotsignpositive. 10 The higher detection rate of spot sign in our study is attributed to the use of CTP technique because unlike CTA, CTP provides an observation of the contrast leakage and dynamic change of spot sign throughout the whole process of scanning. However, recent studies using CTP imaging acquisition also reported that inadequate spatial coverage of hematoma was an important limitation, leading to increased misclassification of CTP spot sign, even with a high detection rate of spot sign. 12, 14 To avoid these limitations, we used whole brain CTP and thin slices to visualize the entire hematoma and minimize misclassification of the spot sign. This suggests that the use of thin-slices whole-brain CTP could improve our ability to detect spot sign-positive patients.
We also found that the predictive ability of CTP spot sign varied according to its timing of occurrence. 19 Based on our results, EOSS before 23.13 seconds was accurate in predicting HE. The positive predictive value of EOSS for HE (PPV=0.82) in our study was much higher than previously reported values (PPV=0.47-0.56). 10, 11 One possible explanation is that more delayed spots were captured and analyzed on CTA, even though they may not have been related to the development of HE, which is consistent with the finding that delayed detection increased sensitivity but not specificity in post hoc analysis of PREDICT study. 11, 20, 21 A recent study found that CTA spot sign was associated with more intraoperative bleeding, more postoperative rebleeding, and larger residual ICH volumes, indicating that spot sign may be a surrogate of continuous bleeding. 22 In our study, we found increased contrast concentration with time on the postcontrast CT, which also suggests an active extravasation and a reverse correlation between timing of CTP spot sign occurrence and ICH volume growth. This suggests that the extravasated contrast gradually accumulated before spot sign could be detected and that the timing of occurrence of CTP spot sign may reflect the speed and volume of ongoing bleeding in hematoma. Our study also demonstrates that EOSS also predicts 3-month mortality with a relatively high specificity. The EOSS maintained a higher specificity compared with CTP spot sign (91% versus 74%). In the context of previous findings that multiphase acquisition including both arterial-and venousweighted images could increase the detection rate, although only early-phase acquisition was associated with greater absolute HE, 12, 20 our definition of spot sign based on the timing of its detection on CTP to identify EOSS, together with the improved detection rate of CTP spot sign, would improve current ability to stratify ICH patients at increased risk for HE.
Our study has some limitations. First, it was performed in a single center with a relatively small sample size. The characterization of the spot sign was based on the CTP parameters in our center, including the rate of contrast bolus injection and the contrast dose. This requires further external validation in future studies. Moreover, it is important to point out that the predictive value of EOSS does not reflect the performance of spot sign on single phase CTA, considering the dynamic observation of EOSS based on CTP. Second, we cannot exclude selection bias because of the retrospective nature of our study. Third, the spot sign-positive patients in our study had a high rate of surgical evacuation of the hematoma, which may lead us to underestimate the spot sign's positive predictive value for mortality.
In conclusion, we demonstrate improved detection rate and sensitivity for predicting HE and mortality with CTP spot sign. We also redefined the spot sign based on timing of contrast leakage on CTP and found that EOSS (before 23.13 seconds) improves the specificity of the spot sign for predicting HE and mortality after SICH. These results suggest that the use of CTP to identify spot sign and EOSS after SICH could improve the selection of ICH patients for potential hemostatic therapy. Our findings require further prospective validation in a larger cohort of SICH patients. 
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